Boston (Hainan) Medical Technology

Boston Scientific (Hainan) Medical Technology is a subsidiary of Boston Scientific established to leverage the preferential policies of the Hainan Boao Lecheng International Medical Tourism Pilot Zone. The company focuses on introducing advanced medical devices and innovative therapies to the Chinese market, often utilizing the "Real-World Study" (RWS) pathway to accelerate regulatory approval. Its portfolio includes minimally invasive technologies for urology, interventional cardiology, and oncology, such as the Rezūm Water Vapor Therapy and TheraSphere Y-90 Glass Microspheres. By operating in Hainan, the company serves as a strategic hub for clinical research and early commercial access to global medical innovations within China.